1 ADENOVIRUS-MEDIATED BAK GENE TRANSFER INDUCES APOPTOSIS IN MESOTHELIOMA CELL LINES Abujiang Pataer, MD, PhD a W. Roy Smythe, MD a Robert Yu, MS a Bingliang Fang, MD, PhD a Tim McDonnell, MD, PhD b Jack A. Roth, MD a Stephen G. Swisher, MD a Objective: Conventional treatment for mesothelioma is largely ineffective. We therefore evaluated the novel approach of adenoviral gene transfer of the proapoptotic Bcl-2 family member Bak in mesothelioma cancer cell lines, which are sensitive and resistant to adenoviral p53. Methods: Binary adenoviral Bak (Ad/GT-Bak and Ad/GV16) and LacZ (Ad/GT-LacZ and Ad/GV16) vectors were used for transduction of the mesothelioma cell lines I-45 (p53 resistant) and REN (p53 sensitive). Protein levels were determined by Western blotting. Apoptosis was assessed by morphologic changes, caspase-3 cleavage, and fluorescence-activated cell sorter analysis of subdiploid populations. Cell viability was determined with the XTT assay. Statistical analysis was performed with analysis of variance and the Student t test. Results: High levels of Bak gene transfer were seen after coadministration of Ad/GT-Bak and Ad/GV16 in both mesothelioma cell lines. Apoptosis was induced 24 hours after Bak but not LacZ gene transfer ([Bak: I-45, 36%; REN, 25%] vs [LacZ: I-45, 1%; REN, 3%], P <.05]) in p53-sensitive (REN) and p53-resistant (I-45) cell lines. Cellular viability was significantly decreased 48 to 72 hours after Bak gene transfer compared with control vector in both cell lines (72 hours: Bak I-45, 1.4% ± 1.0%, and Bak REN, 4.7% ± 1%, vs Lac-Z I-45, 83% ± 3%, and Lac-Z REN, 100% ± 1%; P <.05). Conclusions: Adenovirus-mediated overexpression of the Bak gene induces apoptosis and decreased cellular viability in p53-sensitive and p53-resistant mesothelioma cells. These data suggest that the gene transfer of proapoptotic Bcl-2 family members may represent a novel gene therapy strategy to treat mesothelioma. (J Thorac Cardiovasc Surg 2001;121:61-7) Malignant pleural mesothelioma remains a therapeutic problem. Conventional therapy with surgery, chemotherapy, or radiotherapy has largely been ineffective in curing the majority of patients. 1,2 The advent of gene therapy offers a novel mode of therapy to treat malignant pleural mesotheliomas through the transfer of functional genes. Phase I clinical trials in mesothe- lioma have demonstrated the feasibility of transferring the herpes simplex virus thymidine kinase (HSVtk) gene followed by treatment with the prodrug ganciclovir. 3,4 Another gene therapy strategy that has been reported in locoregionally advanced non small cell lung cancer involves the induction of apoptosis with the transfer of the tumor suppressor p53 gene. 5 From the Section of Thoracic Molecular Oncology, Department of Thoracic and, a and the Department of Molecular Pathology, b The University of Texas M.D. Anderson Cancer Center, Houston, Tex. Supported by grants from the National Institutes of Health (grant PO1 CA A1) to J.A.R., S.G.S., and T.J.M., by Specialized Program of Research Excellence in Lung Cancer Grant P50-CA70907, by gifts to the Division of Surgery and Anesthesiology from Tenneco and Exxon for the Core Laboratory Facility, by the University of Texas M. D. Anderson Cancer Center Support Core Grant CA16672, by a sponsored research agreement with Introgen Therapeutics, and by the W. M. Keck Foundation and by the tobacco settlement funds (project 8). Read at the Eightieth Annual Meeting of The American Association for Thoracic Surgery, Toronto, Ontario, Canada, April 30 May 3, Received for publication May 4, 2000; revisions requested July 25, 2000; revisions received Aug 28, 2000; accepted for publication Sept 9, Address for reprints: Stephen G. Swisher, MD, Department of Thoracic and, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 109, Houston, TX ( Copyright 2001 by The American Association for Thoracic Surgery /2001 $ /6/ doi: /mtc
2 62 Pataer et al The Journal of Thoracic and January 2001 Fig 1. Diagram of binary adenoviral vector Ad/GT-Bak, in which Bak gene expression is controlled by the presence of Gal4/GV16, requiring coadministration of both vectors to induce Bak gene expression. Apoptosis is a conserved pathway in all cells, which, when activated, leads to cellular death by caspase activation and subsequent chromosome condensation and nuclear degradation. 6 Many tumor cells have evaded apoptotic cell death by inactivating p53, which is believed to be an upstream initiator of apoptosis. 7 Replacement of wild-type p53 with gene transfer can lead to apoptosis in lung cancer cells because this allows the apoptotic pathway to be restored. Unlike lung cancer cells, however, many mesothelioma cells fail to undergo apoptosis after p53 gene transfer. The reason for this may be due to the fact that mesothelioma cells have a very low rate of p53 mutations, and therefore gene therapy strategies on the basis of p53 replacement are ineffective because most mesothelioma cells already have functional p53. 8 We therefore decided to evaluate other proapoptotic genes. The Bcl- 2 family is another group of genes important in the regulation of apoptosis with either proapoptotic (Bax and Bak) or antiapoptotic (Bcl-2 and Bcl-X L ) members. 9 We therefore hypothesized that overexpression of the Bak gene would lead to apoptosis in p53-resistant and p53-sensitive mesothelioma cells by overwhelming antiapoptotic Bcl-2 family members (Bcl-2 and Bcl-X l ) and bypassing upstream p53 resistance. To address this question, we used a binary adenoviral vector system containing 2 adenoviral vectors in which one vector, Ad/GT-Bak, contained the Bak gene under control of the GT promoter and the GAL4/GV16 fusion protein. 10 Bak gene expression could then be induced in target tissues by coadministration of the Ad/GT-Bak vector with the second adenoviral vector Ad/GV16, which produced the GAL4/GV16 fusion protein (Fig 1). We have previously shown that Ad/GT-Bak can induce apoptosis in p53-sensitive lung cancer cells in a caspase 3 dependent fashion, 11 but we were unsure whether it could also induce apoptosis in mesothelioma cells that, unlike lung cancer cells, are mostly p53 resistant. To answer this question, we evaluated two mesothelioma cell lines, one that was p53 sensitive (REN, p53 mutant) and one that was p53 resistant (I-45, p53 wild-type). Our findings showed that we were able to induce apoptosis and decreased cell viability in both p53-resistant and p53-sensitive mesothelioma cell lines, suggesting that the induction of apoptosis and cell death in mesothelioma with Ad/GT-Bak may represent a novel treatment. Material and methods Cell lines and antibodies. The REN (inflammatory epithelial subtype, p53 mutant) mesothelioma cell line was developed by one of the authors (W.R.S.) and has been previously described. 4 The I-45 (sarcomatous subtype, p53 wild-type) cell line was originally provided by Dr Joe Testa of the Fox Chase Cancer Center in Philadelphia, Pennsylvania. All cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum, 10 mmol/l glutamine, 100 U/mL penicillin, and 100 µg/ml streptomycin (Life Technologies, Inc, Grand Island, NY) in a 5% carbon dioxide atmosphere at 37 C. The following antibodies were used: monoclonal antibody to Bcl- X L was obtained from Santa Cruz Biotechnology (Santa Cruz, Calif). The polyclonal antibody to CPP32 (caspase 3) was purchased from PharMingen (San Diego, Calif). The polyclonal antibodies raised against Bak, Bax, and β-actin were bought from Santa Cruz Biotechnology. Adenovirus production and transduction. Construction of the Ad/GT-LacZ, Ad/GV16, and Ad/GT-Bak vectors have
3 The Journal of Thoracic and Volume 121, Number 1 Pataer et al 63 Fig 2. Western blot analysis of the expression of Bak, Bax, and Bcl-X L in cell lysates 24 hours after treatment with PBS (lanes 1), Ad/GT-LacZ (lanes 2), and Ad/GT-Bak (lanes 3). The expression level of actin was used as a control. been reported previously. 10,11 The binary adenoviral vector system required coadministration of Ad/GT-Bak and Ad/GV16 (hereafter described as Ad/GT-Bak) or Ad/GT- LacZ and Ad/GV16 (hereafter described as Ad/GT-LacZ). The transduction efficiencies of the cell lines were determined with Ad/GT-LacZ and Ad/GV16. Subsequent experiments used viral titers needed to transduce at least 90% of the cells (MOI, 2400 viral particles = 1600 viral particles [Ad/GT-Bak] viral particles [Ad/GV16]). Western blot analysis. Total cell lysates were prepared by lysing cell monolayers in plates with sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE). Each lane was loaded with 5 µg of cell lysate protein, as determined by BCA protein assay (Pierce, Rockford, Ill). Subsequently, proteins were separated under reducing conditions on an SDS polyacrylamide gel. After electrophoresis at 20 ma for 2 hours, the proteins in the gels were transferred to Hybond-ECL membranes (Amersham Corp, Arlington Heights, Ill). Then the membranes were blocked with 1% dry milk and 0.1% Tween-20 (Sigma, St Louis, Mo) and incubated with primary antibodies. The membranes were then incubated with secondary antibody conjugated with horseradish peroxidase (Amersham, Piscataway, NJ). The membranes were developed according to the Amersham ECL protocol. Relative quantities of protein were determined by using a densitometer (Molecular Dynamics Inc, Sunnyvale, Calif). Apoptosis analysis. Apoptotic cell death was examined by assessment of cell morphology after Hoechst staining and flow cytometric analysis of cells for propidium iodide exclusion 24 to 48 hours after transduction. Specimens were analyzed in an EPICS Profile II flow cytometer (Coulter Corp, Hialeah, Fla). Additionally, caspase cleavage was assessed by means of Western blotting to determine activation of the execution phase of apoptosis. Cellular viability analysis. Cells were grown in 96-well plates in 100 µl volume per well. On the first day, cells were transduced with Ad/GT-Bak or control vectors. On the second day, the cells were incubated with the tetrazolium salt XTT for 4 to 24 hours, according to the Roche protocol (Roche Diagnostics, Mannheim, Germany). Viability was assessed spectrophotometrically on an enzyme-linked immunosorbent assay (ELISA) plate reader. Statistical analysis. Data in the figures represent the mean of 3 independent experiments with the SD. Analysis of variance and the 2-tailed Student t test were used for statistical analysis. Results Transduction of mesothelioma cells by Ad/GT-Bak and Ad/GV16. The mesothelioma cell lines used in these experiments included cells with null p53 (REN) and wild-type p53 (I-45) genotypes. The titers used for these experiments were determined by experiments with Ad/GT-LacZ, which demonstrated that the binary adenoviral vector system achieved over 90% transduction efficiencies with 2400 viral particles (1600 Ad/GT-Bak plus 800 Ad/GV16). Only low levels of endogenous Bak protein were observed in cells treated with phosphatebuffered saline solution (PBS) or infected with Ad/GT- LacZ, whereas high levels of Bak protein were seen as early as 24 hours after transduction with Ad/GT-Bak (Fig 2). The levels of proapoptotic Bax and antiapoptotic Bcl- X L did not change after viral transduction with either control or Ad/GT-Bak vectors (Fig 2). Induction of apoptosis in mesothelioma cells by Ad/GT-Bak. Transduction of the mesothelioma cell lines with Ad/GT-Bak induced morphologic changes
4 64 Pataer et al The Journal of Thoracic and January 2001 A B C Fig 3. Hoechst staining of mesothelioma cells 24 hours after treatment with PBS (A), Ad/GT-LacZ (B), or Ad/GT- Bak (C). Only the cells treated with Ad/GT-Bak showed the presence of cytoplasmic contraction, membrane blebbing, and the formation of apoptotic bodies. Table I. Induction of apoptosis in mesothelioma cell lines after Ad/GT-Bak transduction Apoptosis Mesothelioma cell line PBS control* Ad/GT-LacZ* Ad/GT-Bak* Adenoviral p53* I-45 (p53 wild-type) 1% ± 1% 1% ± 1% 36% ± 3% 5% ± 2% REN (p53 mutant) 2% ± 1% 3% ± 1% 25% ± 4% 30% ± 5% *Mean of 3 experiments ± SD. P <.05 accepted as statistically significant. within 24 hours. Cells treated with Ad/GT-Bak became shrunken and dense appearing, often detaching from the cell plates, whereas cells from the other control groups remained in monolayers with normal morphology. Hoechst staining was performed and revealed the presence of cytoplasmic contraction, membrane blebbing, and the formation of apoptotic bodies in the Ad/GT-Bak treated cells (Fig 3). To determine whether these changes were due to apoptosis, propidium iodide staining and fluorescence-activated cell sorter analysis was performed, looking for subdiploid populations. As Table I shows, Ad/GT-Bak treatment induced apoptosis in both the p53-sensitive (REN) and p53-resistant (I- 45) cell lines as early as 24 hours after transduction. Additional evidence for the induction of apoptosis by Ad-GT-Bak included demonstration of caspase 3 cleavage from the inactive proenzyme to the activated 17-kd fragment, which is associated with onset of the execution phase of apoptosis (Fig 4). Cleavage of the caspase 3 proenzyme was noted in both mesothelioma cell lines and was not seen in cells treated with control vector (Ad/GT-LacZ) or PBS. Decreased cellular viability in mesothelioma cells after Ad/GT-Bak. Cellular viability was assessed with the XTT assay. Transduction of both the p53-sensitive (REN) and p53-resistant (I-45) mesothelioma cell lines resulted in marked decrease in cellular viability 48 to 72 hours after infection (Fig 5). The REN (mutant p53) demonstrated 18% ± 3% viability at 48 hours and 4.7% ± 1% at 72 hours. The I-45 (wild-type p53) cell line showed only 7.7% ± 2.5% viability at 48 hours and 1.4% ± 1% at 72 hours. Treatment with control vector resulted in no decreased viability in REN cells but did note some decrease at 72 hours in I-45 cells 83% ± 3%. Discussion Malignant pleural mesothelioma is a tumor that is unresponsive to standard modalities of cancer treat-
5 The Journal of Thoracic and Volume 121, Number 1 Pataer et al 65 Fig 4. Western blot analysis of the expression of Bak and caspase 3 in cell lysates 24 hours after treatment with PBS (lanes 1), Ad/GT-LacZ (lanes 2), and Ad/GT-Bak (lanes 3). The expression level of actin was used as a control. A B Fig 5. XTT assessment of cellular viability 24 to 72 hours after transduction of I-45 (A) or REN mesothelioma cells (B) with PBS, Ad/GT-LacZ, or Ad/GT-Bak.
6 66 Pataer et al The Journal of Thoracic and January 2001 ment. 1,2 Gene therapy offers the opportunity of a new modality of therapy for this fatal disease. A recently completed phase I clinical trial in mesothelioma demonstrated the feasibility of treating malignant mesothelioma with intrapleural instillation of herpes simplex virus thymidine kinase (HSVtk). 3 In that study 21 patients were treated with minimal toxicity with a replication-incompetent adenoviral vector containing the gene encoding HSVtk. Other gene therapy strategies include the induction of apoptosis with the transfer of the tumor suppressor p53 gene. One recently completed trial in non small cell lung cancer demonstrated clinical responses with adenovirus-mediated overexpression of wild-type p53 in patients in whom all conventional treatments had failed. 5 It is clear, however, that not all patients respond to adenoviral p53. Additionally, preclinical experience with mesothelioma cell lines have demonstrated p53 resistance in a number of cell lines. We therefore evaluated the effectiveness of adenoviral transfer of the proapoptotic Bak gene in mesothelioma cell lines. The induction of apoptosis or programmed cell death reflects a balance between signaling events and molecules that either promote or inhibit apoptosis. 6,12 Current data support the hypothesis that within the Bcl-2 family, the ratio of death antagonist to agonist determines whether a cell will respond to apoptotic signals. 13 This hypothesis favors the use of adenoviral vectors because they are able to induce high levels of gene expression, which would presumably overwhelm the levels of antiapoptotic Bcl-2 members. Our observations support this hypothesis because Ad/GT-Bak was able to induce apoptosis, even in the presence of high endogenous levels of antiapoptotic Bcl-X L (Fig 2). Our previous study demonstrated that adenovirusmediated overexpression of Bak could induce apoptosis in p53-sensitive lung cancer cells. 11 This study demonstrated the novel observation that Ad/GT-Bak could also induce apoptosis in cells that are resistant to p53. The observation that p53-resistant mesothelioma cell lines are sensitive to Ad/GT-Bak is not necessarily expected because p53 works in part by up-regulating Bak and Bax. 14,15 It may be that the very high tissue levels of Bak achieved with adenoviral vectors allows adenoviral Bak gene transfer to be effective. Additionally, Bak may be acting downstream from p53 in the apoptotic cascade, thus allowing it to bypass a genetic blockage further upstream in the cascade. It is important to note, however, that even though Bak gene transfer is not p53 dependent, the process appears caspase dependent because cell lines that lack functional caspase 3 are resistant to Parp cleavage and development of subdiploid populations by fluorescence-activated cell sorter analysis. 11 The increased apoptotic potential of Ad/GT-Bak may come at a price, however, because we have observed that Ad/GT-Bak appears less selective than adenoviral p53 and more likely to induce apoptosis in normal human bronchial epithelial cells (data not shown). Clinical strategies to overcome toxicity to normal tissue include tumor selective promoters, such as the telomerase or DF3 promoter. 10,16 Alternatively, as experience with HSVtk demonstrates, direct intrapleural instillation may allow proportionally more mesothelioma tumor cells to be transduced, thereby minimizing toxicity to normal tissue. In summary, we have shown that adenovirus-mediated overexpression of Bak leads to rapid apoptosis in mesothelioma cells. This antitumor strategy does not appear dependent on p53 sensitivity, p53 genetic status, or level of antiapoptotic Bcl-X L. The lack of selectivity for normal and cancer cells may require strategies, such as tumor selective expression or intrapleural localization, to avoid toxicity to normal tissues. Because this adenovirus-based strategy does not require p53 and induces apoptosis in p53-resistant tumors, it may ultimately provide a novel gene therapy strategy for patients with malignant pleural mesothelioma. We thank S. Russo and K. Hunt for help in the preparation and review of the article. REFERENCES 1. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus P, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J Clin Oncol 2000;16: Law MR, Gregor A, Hodson ME, Bloom HJG, Warwick MT. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984;39: Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9: Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994;54: Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non small cell lung cancer. J Natl Cancer Inst 1999;91: Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997;88: Shimamura A, Fisher DE. p53 in life and death. Clin Cancer Res 1996;2:
7 The Journal of Thoracic and Volume 121, Number 1 Pataer et al Mor O, Yaron P, Huszar M, et al. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 1997;16: Korsmeryer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bc1-2/Bax: a rheostat that regulates anti-oxidant pathway and cell death. Cancer Biol 2000;4: Fang B, Ji L, Bouvet M, Roth JA. Evaluation of GAL4/TATA in vivo: induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem 1998;273: Pataer A, Fang B, Yu R, et al. Adenoviral bak overexpression mediates caspase-dependent tumor killing. Cancer Res 2000;60: Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78: Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl- 2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993;4: Pearson AS, Spitz FR, Swisher SG, et al. Up-regulation of the proapoptotic mediators bax and bak following adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res 2000;6: Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 1995;80: Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 1999;59: Discussion Dr Nasser K. Altorki (New York, NY). Dr Swisher, I have a couple of questions for you. Correct me if I am wrong, but I had the impression that the bcl-2 mediated apoptotic mechanism is also to some extent p53 dependent. Is that not so? Dr Swisher. You are quite right. p53 appears to induce apoptosis through a cascade with p53 at the top, inducing other proapoptotic genes, such as proapoptotic Bcl-2 family members like Bak, which then induce activated caspases to dismantle the cell. Our interest in the Bcl-2 family was that we thought if there were functional problems with p53 up higher, then perhaps we could induce apoptosis further down the cascade through the Bcl-2 family and overcome some of the p53 resistance noted in mesothelioma cells. In fact, we have previously shown that transduction of lung cancer cells with adenoviral p53 leads to elevated levels of proapoptotic Bak and Bax, which may be responsible for the induction of apoptosis seen after p53 gene transfer. Dr Altorki. Obviously, this is an impressive piece of work. How do you envision doing that in a model of mesothelioma? It seems to me that the delivery may not be quite as simple. Dr Swisher. There are obviously 2 problems in translating adenoviral Bak gene therapy to the clinical arena in mesothelioma. The first problem is the preclinical one, which we have looked at in this study, and that is how apoptosis in mesothelioma cells is induced. The second problem is how this can be effective clinically. I agree that one of the biggest problems with gene transfer in mesothelioma is the difficulty of delivering the vector to the pleural surface because of the loculations within the hemithorax. Therefore, I would envision delivering the vector in conjunction with an operation, perhaps after a pleural pneumonectomy, when the gross disease and loculations have been removed, to get those residual small cells that are remaining. Dr David J. Sugarbaker (Boston, Mass). I have one brief question that Dr Altorki touched on. With the data now showing that improved local control of mesothelioma in human subjects undergoing either pleural pneumonectomy or other more radical operations, we are beginning to see systemic metastases, more so than in the past. Can you speculate as to how you might deliver this system systemically to affect not just the hemithorax but also a systemic distribution? Dr Swisher. One of the problems with adenoviral gene transfer is trying to target systemic micrometastases. You can get high levels of expression intratumorally with direct injection, but it is difficult to get high levels systemically through the bloodstream. I think there may be potential in the future to address systemic micrometastases with liposomes. In addition, some work has been done recently to target these liposomes to cell surface receptors. I notice that an upcoming presentation in this forum documents high levels of folate receptors in mesothelioma cells, and one can target the liposomes to these receptors. Theoretically, with a liposomal targeting system, one may be able to address systemic micrometastases in the future. Bound volumes available to subscribers Bound volumes of The Journal of Thoracic and are available to subscribers (only) for the 2001 issues from the Publisher, at a cost of $ for domestic, $ for Canadian, and $ for international subscribers for Vol 121 (January-June) and Vol 122 (July-December). Shipping charges are included. Each bound volume contains a subject and author index and all advertising is removed. Copies are shipped within 60 days after publication of the last issue of the volume. The binding is durable buckram with the Journal name, volume number, and year stamped in gold on the spine. Payment must accompany all orders. Contact Mosby, Subscription Customer Service, 6277 Sea Harbor Dr, Orlando, FL 32887,USA; phone or Subscriptions must be in force to qualify. Bound volumes are not available in place of a regular Journal subscription.
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
ELISA BIO 110 Lab 1 Immunity and Disease Introduction The principal role of the mammalian immune response is to contain infectious disease agents. This response is mediated by several cellular and molecular
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
Application Note No. 2 / July 2012 Quantitative Assessment of Cell Quality, Viability and Proliferation System Quantitative Assessment of Cell Quality, Viability and Proliferation Introduction In vitro
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not
The Evaluation of Interferon-beta Levels in HPV-positive Cervical Cancer Cell Lines Olivia M. Ford and Jennifer T. Thomas, Ph.D. Human Papillomavirus (HPV) is the most common viral sexually transmitted
CASE STUDY High Content Image Analysis Inhibition of MicroRNA Sensitizes 3D Breast Cancer Microtissues to Radiation Therapy Dr. Nataša Anastasov leads the Personalized Radiation Therapy Group within the
Western Blot Analysis with Cell Samples Grown in Channel-µ-Slides Polyacrylamide gel electrophoresis (PAGE) and subsequent analyses are common tools in biochemistry and molecular biology. This Application
CUSTOM ANTIBODIES Highly competitive pricing without compromising quality. Rat monoclonal antibodies for the study of gene expression and proteomics in mice and in mouse models of human diseases available.
prosci-inc.com Custom Antibody Services High Performance Antibodies and More Broad Antibody Catalog Extensive Antibody Services CUSTOM ANTIBODY SERVICES Established in 1998, ProSci Incorporated is a leading
Bottlenecks in Clinical Source Material Acquisition Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA email@example.com Biopreservation What s the issue? Biopreservation considerations
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
LESSON 3.5 WORKBOOK How do cancer cells evolve? In this unit we have learned how normal cells can be transformed so that they stop behaving as part of a tissue community and become unresponsive to regulation.
Paclitaxel-Loaded Expansile Nanoparticles Enhance Chemotheraputic Drug-delivery in Mesothelioma 3D Multicellular Spheroids Hongyi Lei 1, Rong Liu 1, Aaron Colby 2, Mark W. Grinstaff 2, Yolonda L. Colson
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
Virological Methods Flint et al. Principles of Virology (ASM), Chapter 2 Overview The most commonly used laboratory methods for the detection of viruses and virus components in biological samples can be
Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production
a Beckman Coulter Life Sciences: White Paper Violet-Excited nim-da Allows Efficient and Reproducible Cell Cycle Analysis on the Gallios Flow Cytometer Authors: Valdez, Ben 1. Carr, Karen 2. Norman, John
Molecular Cancer Therapeutics 545 Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma Mustafa K. Ozvaran, 1 Xiaobo X. Cao, 1 Steven D. Miller, 1
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
Gene Therapy (1997) 4, 280 287 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene MC Esandi
Disclosure Equity interest in Genetix Pharm. Inc. Exclusive license of retroviral cell lines from Columbia No direct participation in MDR clinical trials Columbia U. annual reporting FDA Gene Therapy Transfer
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
Programa Cooperación Farma-Biotech Jornada II: Oncología Novel Berberine derivatives as antitumor agents for cancer Barcelona, 13 de abril de 2011 Programa Cooperación Farma-Biotech Jornada II: Oncología
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
Homeopathy Efficacy of Ruta Graveolens in Brain Cancer & Leukemia C.Health Tue, Sep-06-05, 06:27 This study from the International Journal of Oncology shows how the homeopathic remedy Ruta 6 used in conjunction
No Disclosures Gregory A. Brent, MD Departments of Medicine and Physiology David Geffen School of Medicine at UCLA VA Greater Los Angeles Healthcare System Learning Objectives Describe the pathways that
Understanding the immune response to bacterial infections A Ph.D. (SCIENCE) DISSERTATION SUBMITTED TO JADAVPUR UNIVERSITY SUSHIL KUMAR PATHAK DEPARTMENT OF CHEMISTRY BOSE INSTITUTE 2008 CONTENTS Page SUMMARY
Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159 Investigator: Institution: Carol Wyatt Kansas State University Date Submitted: 12-11-09 Industry summary: Effective circovirus vaccines
Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes Becoming a cancer cell isn t easy One of the fundamental molecular characteristics of cancer is that it does not develop all at once, but
Methionine Sulfoxide Immunoblotting Kit Item No. 600160 Customer Service 800.364.9897 * Technical Support 888.526.5351 www.caymanchem.com TABLE OF CONTENTS GENERAL INFORMATION 3 Materials Supplied 4 Precautions
Plaintiffs Experts Latest Pathological Theories Kurt B. Gerstner Campbell Campbell Edwards & Conroy, P.C. One Constitution Center Boston, MA 02129 (617) 241-3086 firstname.lastname@example.org Kurt
Anti-ATF6 α antibody, mouse monoclonal (1-7) 73-500 50 ug ATF6 (activating transcription factor 6) is an endoplasmic reticulum (ER) membrane-bound transcription factor activated in response to ER stress.
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
Head of College Scholars List Scheme Summer Studentship Report Form This report should be completed by the student with his/her project supervisor. It should summarise the work undertaken during the project
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
INTERNATIONAL JOURNAL OF ONCOLOGY 31: 241-252, 2007 241 In vitro combination characterization of the new anticancer plant drug ß-elemene with taxanes against human lung carcinoma JINSHUN ZHAO 1*, QINGDI
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC email@example.com Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
GeneCust Europe Laboratoire de Biotechnologie du Luxembourg S.A. 6 rue Dominique Lang L-3505 Dudelange Luxembourg Tél. : +352 27620411 Fax : +352 27620412 Email : firstname.lastname@example.org Web : www.genecust.com
Chapter 6: Antigen-Antibody Interactions I. Strength of Ag-Ab interactions A. Antibody Affinity - strength of total noncovalent interactions between single Ag-binding site on an Ab and a single epitope
Edvo-Kit #S-70 How Does a Doctor Test for AIDS? S-70 Experiment Objective: The Human Immunodefi ciency Virus (HIV) is an infectious agent that causes Acquired Immunodefi ciency Syndrome (AIDS) in humans.
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
European Medicines Agency London, 30 May 2008 Doc. Ref. EMEA/CHMP/GTWP/60436/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON FOLLOW-UP OF PATIENTS ADMINISTERED WITH GENE THERAPY
DNA Fingerprinting Unless they are identical twins, individuals have unique DNA DNA fingerprinting The name used for the unambiguous identifying technique that takes advantage of differences in DNA sequence
Chapter 11 Rapid Screening of Gli2/3 Mutants Using the Flp-In System Abstract Gli2 and Gli3 respond to the Hedgehog (Hh) signal in mammals by undergoing posttranslational modifications and moving to the
Manuscript EMM-2011-00864 Enhanced cytotoxicity of PARP inhibition in Mantle Cell Lymphoma harboring mutations in both ATM and p53 Chris T. Williamson, Eiji Kubota, Jeffrey D. Hamill, Alexander Klimowicz,
CancerStemCell Markers in Lung Cancers: Proofsof ConceptsandSome Reservations Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany Lung cancer: highest death rate and poorest patient survival
Chapter 6 Antigen-Antibody Interactions: Principles and Applications Antigen-Antibody Properties You must remember antibody affinity (single) VS avidity (multiple) High affinity: bound tightly and longer!
Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health
CUSTOM POLYCLONAL ANTIBODY DEVELOPMENT QED is committed to excellence across all facets of our operations, and to responding to the ever-changing needs of our customers. We have been developing monoclonal
www.sciencesignaling.org/cgi/content/full/7/339/ra80/dc1 Supplementary Materials for Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members Julia T. Warren,
Using Viruses to Kill Cancer: Investigating the role of in vitro cell differentiation in HSV-1 double-mutant KM110red infection of hfob and U2OS cells Natalie Raso Background In the successful development
Chapter 3 Contd. Western blotting & SDS PAGE Western Blot Western blots allow investigators to determine the molecular weight of a protein and to measure relative amounts of the protein present in different
1 Supplemental data Supplemental Fig. S1. The schematic diagrams of the expression constructs used in this study. Supplemental Fig. S2. Ingenuity Pathway Analysis (IPA) of the 56 putative caspase substrates
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
292PR 01 G-Biosciences 1-800-628-7730 1-314-991-6034 email@example.com A Geno Technology, Inc. (USA) brand name Classic Immunoprecipitation Utilizes Protein A/G Agarose for Antibody Binding (Cat.
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma